Healthcare

In a changing society, PE finds growing opportunities in fertility

Littlejohn to take majority stake in Outcome Health

Littlejohn & Co LLC is acquiring a majority stake in Outcome Health, a healthcare innovation company. No financial terms were disclosed.

PE HUB Healthcare Wire Highlights, 5.9.19

Opportunity emerges at nexus of regenerative medicine, medical device segments

VC-backed Cortexyme goes public

South San Francisco-based Cortexyme Inc, a developer of drugs focused on treating Alzheimer’s disease and other degenerative diseases, has debuted its IPO after pricing its over 4.4 million shares at $17 per share. The stock began trading May 9, 2019 on the NASDAQ under the ticker symbol "CRTX." BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are the lead underwriters. Cortexyme's pre-IPO backers included Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures.

Provepharm Life Solutions rakes in $47.6 mln

Provepharm Life Solutions, a French pharmaceutical and life sciences company, has secured a $47.6 million loan. The backers include Société Générale, BNP Paribas, Banque Populaire Méditerranée and Crédit Agricole Alpes Provence. The capital will be used for acquisitions.

Boston Scientific to buy VC-backed Vertiflex

Boston Scientific said May 9 that it agreed to buy Vertiflex Inc. The deal calls for $465 million in upfront cash with additional payments contingent on commercial milestones for the next three years. Vertiflex has developed a device to improve improve physical function and reduce pain in patients with lumbar spinal stenosis. Vertiflex has raised about $160 million in funding from investors including Endeavour Vision, H.I.G Capital and H.I.G. BioVentures, according to PitchBook.

Great Point Partners invests in Axiom Real-Time Metrics

Axiom Real-Time Metrics, a Toronto-based provider of e-clinical solutions, has raised a “significant” undisclosed investment from Great Point Partners, a U.S. healthcare private equity firm. Founded in 2001 by CEO Andrew Schachter, Axiom provides data management, data analytics, biostatistics, pharmacovigilance and other services that support the clinical study data and operational needs of small and mid-sized life sciences companies. The investment by GPP is Axiom’s first from an external capital source. The proceeds will be used for enhancements to Axiom’s Fusion eClinical platform and growth of professional services and business development initiatives.

Metalmark seeks buyer for device maker focused on tissue repair, Collagen Matrix

Ampersand Capital backs GenDx

Ampersand Capital Partners has made a minority investment in GenDx, a Dutch provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. No financial terms were disclosed.

Arsenal's deal for Hopebridge valued at ~$255 mln